2021 ASCO Review
To provide a comprehensive overview of topics of greatest importance as presented at the 2021 ASCO Annual Meeting.
Target Audience
Oncologists and other health care professionals working with individuals with cancer.
Additional Information
Attachment | Size |
---|---|
ASCO Handout - Brochure 2021 (Final).pdf | 263.13 KB |
The ASCO conference for October 29th is now virtual only.
Faculty Disclosures:
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
• Antoinette J. Wozniak, MD – Consultant: Lilly Oncology, Regeneron, Epizyme, GlaxoSmith Kline, Novocure, Janssen Inc, Incyte, and Beigene. Other: DSMB BeyondSpring, DSMB Odronate, DSMB HUYA.
• Jason Luke, MD – Other: DSNB AbbVie, DSMB Immutep, Other/Advisory Board: (7 Hills, Fstar, Inzen, Refle Xion, Xilio, Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, Onc.Al, Pyxis, Tempest, Consultant: AbbVie, Alnylam, Avillion, Bayer, Bristol Meyer Squibb, Checkmate, Codiak, Crown, Day One, Eisai, EMD Serono, Flame, Genentech, Gilead, HotSpot, Kadmon, KSQ, Janssen, Ikena, Immunocore, Incyte, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, Synthekine, TRex, Werewolf, Xencor Research and Support: AbbVie, Agios (IIT), Astellas, AstraZeneca, Bristol-Meyers Squibb (IIT an d Industry), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Pfizer (IIT and Industry), Replimmune, Rubis, Scholar rock, Synlogic, Takeda, Trishula, Tizona, Xencor Patents: (both provisional) Serial # 15/612,657, (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1: Diagnostic, Prognostic and Therapeutic Uses Thereof)
• Dan Zandberg, MD – Grant/Research Support: (for my role as PI for trails with): Merck, Bristol Myers-Squibb, Aduro, Glaxo Smith-Kline, Lilly, Checkmate Pharmaceuticals, BICARA, Aethlon, Prelude Therapeutics Consultant: Macrogenics, Blueprint Medicine
• Shannon Puhalla, MD – Grant/Research Support: AbbVie, Pfizer, Lilly, Novartis, Incyte, Covariance-Bayer, AstraZeneca.
Consultant: AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring.
• Adam Brufsky, MD, PhD, FACP – Consultant: Roche, Puma, Seattle Genetics, AstraZeneca, Daiichi, Pfizer, Novartis.
• Yana Najjar, MD – Grant/Research Support: Merck, Bristol Meyer Squibb, Pfizer Consultant: Novartis, Array BioPharma, Merck
• Leonard Appleman, MD, PhD – Consultant: AADi Grant/Research Support: Pfizer, Exelixis, Bristol Meyer Squibb, Astellas Pharma, Novartis, Bayer, Merck, Genentech/Roche, AVEO, Peleton Therapeutics, Calithera Bioscience, Seattle Genetics, Inovia Pharmaceuticals, Eisai, Lilly, Amgen, Surface Oncology, BioNTech, Epizyme.
Other: Pfizer, Exelixis
• Taofeek Owonikoko, MD – Research/Funding: Novartis, Astellas Pharma, Bayer, StemCentRX, Regeneron, AstraZeneca, G1 Therapeutics, Bristol Myers, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer Aeglea Biotherapeutics, Incyte, Merck, Mersana, Turning Point, Oncorus, Ispen, Eisai, Roche/Genentech Consultant/Advisory Board: Novartis, Lilly, Sandoz, AbbVie, Eisai, G1 Therapeutics, Bristol-Meyer Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, XCovery, Bayer, heron Pharmaceutical, ARMO, BioSeience, Merck, Bayer, Jazz, Zentalis, Ipsen IRC/DSMB: Serono, Roche/Genentech, Other: Cambium Oncology
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation and Designation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing (CNE)
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.75 contact hours.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity
Available Credit
- 5.75 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 5.75 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 5.75 Attendance
We gratefully acknowledge support from the following for this activity:
Exhibitors:
AstraZeneca
Eisai Oncology
Advanced Accelerator Applications
Lilly Oncology
Seagen
Agendia, Inc
Merck & Co. Inc
Bristol Meyers Squibb
Genentech "A member of the Roche Group"
Novartis Oncology
Price
Online Registration is now closed.
Registration Categories and Fees:
UPMC Physicians: no charge
UPMC Staff: no charge
Non UPMC Physicians: $75.00
Non UPMC other disciplines$50.00
All cancellations must be sent via email to Becky McClelland at email mcclellandr2@upmc.edu. Cancellations received before October 1, 2021 will be refunded in full. After October 2,2021, a $20 fee will be assessed and no refunds will be made after October 15, 2021.
For more information, contact Becky McClelland at mcclellandr2@upmc.edu or 412-623-3661.